Sort by
Refine Your Search
-
Listed
-
Employer
- University of Oxford
- KINGS COLLEGE LONDON
- ;
- University of Oxford;
- University of London
- King's College London
- The University of Edinburgh;
- UNIVERSITY OF VIENNA
- AALTO UNIVERSITY
- Aston University
- Durham University
- Heriot Watt University
- Heriot-Watt University;
- Imperial College London;
- King's College London;
- Medical Research Council
- Northumbria University;
- University of Cambridge
- University of Dundee;
- University of Newcastle
- 10 more »
- « less
-
Field
-
help develop and characterise advanced patient-derived tumour models and use them to test promising therapeutic targets that exploit vulnerabilities caused by loss of the SMARCB1 gene. This role offers
-
in preventing immune-mediated pathology in autoimmunity remains poorly understood. Using genetic and antibody-based targeting, we aim to dissect how these pathways modulate T-cell signalling
-
characterising binding interactions. You will drive the completion of several mature projects to publication, including revealing new roles for disordered domains in efficient DNA target search. You may also
-
into disease progression, with the ultimate aim of identifying novel biomarkers and therapeutic targets. You will hold a relevant PhD/DPhil, together with sufficient specialist knowledge in normal and malignant
-
targets. You will hold a relevant PhD/DPhil, together with sufficient specialist knowledge in normal and malignant hematopoiesis research. Experience generating genomics data from leukaemia samples with
-
dedicated high-performance computing implementations. Technology transfer to magnetic resonance imaging in medicine is a secondary target. Key Duties and Responsibilities The postholder will develop new image
-
and electrophysiology approaches. Age-related metabolites will be targeted to improve the efficiency of generating functional hiPSC-CMs to improve therapeutic options for aged patients. The results
-
therapeutic targets. The individual will report to the PI of the headache Group, Dr Philip R Holland and will be responsible for conducting their own independent research projects, the supervision of more
-
precancers and developing targeted interventions, including vaccines, to intercept them. The project focuses on designing, validating, and preclinically testing neoepitope-based mRNA vaccines to prevent BRCA
-
-impact journal articles, particularly targeting evidence-based healthcare design and architectural research. Engage in project dissemination through workshops, conferences, and publications. Undertake